Literature DB >> 16151394

Monoclonal antibody successes in the clinic.

Janice M Reichert1, Clark J Rosensweig, Laura B Faden, Matthew C Dewitz.   

Abstract

Most monoclonal antibodies in clinical trials are owned by small biotech companies. But with blockbuster-sized revenues and approval rates higher than those for small-molecule drugs, that all may be set to change.

Mesh：

Substances：

Year:  2005        PMID： 16151394     DOI： 10.1038/nbt0905-1073

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


  176 in total

1.  Rabbit monoclonal antibody: potential application in cancer therapy.

Authors:  Lifeng Feng; Xian Wang; Hongchuan Jin
Journal:  Am J Transl Res       Date:  2011-04-23       Impact factor: 4.060

Review 2.  Development of anti-infectives using phage display: biological agents against bacteria, viruses, and parasites.

Authors:  Johnny X Huang; Sharon L Bishop-Hurley; Matthew A Cooper
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

3.  General strategy for the generation of human antibody variable domains with increased aggregation resistance.

Authors:  Kip Dudgeon; Romain Rouet; Iris Kokmeijer; Peter Schofield; Jessica Stolp; David Langley; Daniela Stock; Daniel Christ
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-27       Impact factor: 11.205

Review 4.  Development trends for human monoclonal antibody therapeutics.

Authors:  Aaron L Nelson; Eugen Dhimolea; Janice M Reichert
Journal:  Nat Rev Drug Discov       Date:  2010-09-03       Impact factor: 84.694

5.  Development of a novel mammalian cell surface antibody display platform.

Authors:  Chen Zhou; Frederick W Jacobsen; Ling Cai; Qing Chen; Weyen David Shen
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

6.  The future of monoclonal antibody technology.

Authors:  Alexander Zider; Donald L Drakeman
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

Review 7.  Stability of IgG isotypes in serum.

Authors:  Ivan R Correia
Journal:  MAbs       Date:  2010-05-16       Impact factor: 5.857

Review 8.  Clinical pharmacokinetics of therapeutic monoclonal antibodies.

Authors:  Ron J Keizer; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2010-08       Impact factor: 6.447

9.  Long-lasting protective antiviral immunity induced by passive immunotherapies requires both neutralizing and effector functions of the administered monoclonal antibody.

Authors:  Roudaina Nasser; Mireia Pelegrin; Henri-Alexandre Michaud; Marc Plays; Marc Piechaczyk; Laurent Gros
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

Review 10.  Metrics for antibody therapeutics development.

Authors:  Janice M Reichert
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.